Pharvaris

PHVSPhase 3

Pharvaris is a clinical-stage biotech focused on transforming the treatment landscape for hereditary angioedema (HAE) and other bradykinin-mediated conditions by developing oral alternatives to current injectable therapies. The company's lead asset, deucrictibant, is a potent, oral small-molecule B2 receptor antagonist being evaluated in two pivotal Phase 3 trials (RAPIDe-3 for on-demand and CHAPTER-3 for prophylaxis) and has shown promising efficacy and safety in Phase 2 studies. With a seasoned leadership team and a clear mission to provide patient choice through convenient, effective oral treatments, Pharvaris is positioned to address significant unmet needs in the rare disease market.

Market Cap

$1.7B

Focus

Small Molecules

PHVS · Stock Price

USD 26.00+8.33 (+47.14%)

Historical price data

AI Company Overview

Technology Platform

Rational design of oral small-molecule antagonists targeting the bradykinin B2 receptor, with optimized immediate-release and extended-release formulations for on-demand and prophylactic treatment of angioedema attacks.

Pipeline Snapshot

8 drugs in pipeline, 6 in Phase 3

Drug	Indication	Stage
Deucrictibant, Placebo	Hereditary Angioedema	Phase 3
Deucrictibant	Hereditary Angioedema (HAE)	Phase 3
Deucrictibant + Placebo	Hereditary Angioedema (HAE)	Phase 3
Deucrictibant + Placebo + Deucrictibant + Placebo + Deucrictibant	Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)	Phase 3
Icatibant + Placebo	Intradialytic Hypotension	Phase 3

Funding History

Total raised: $60M

IPOUndisclosedUndisclosedFeb 15, 2021

Series B$60MVenrockJun 15, 2020

Opportunities

The primary opportunity is capturing significant market share in the multi-billion dollar HAE therapy market by offering a convenient, effective, and well-tolerated oral alternative to injectables.

Success could also allow expansion into other bradykinin-mediated conditions like AAE-C1INH, creating a franchise in angioedema.

Risk Factors

Key risks include clinical trial failure in ongoing Phase 3 studies, regulatory setbacks, intense competition from established injectable and oral therapies, and the financial and operational challenges of commercializing a drug in the rare disease space as a pre-revenue company.

Competitive Landscape

Main competitors include Takeda (lanadelumab, icatibant), BioCryst (berotralstat), and CSL Behring (C1-inhibitors). Pharvaris differentiates by targeting the B2 receptor with an oral therapy designed for both prophylaxis and on-demand use, aiming for a best-in-class tolerability profile compared to the only other oral drug, berotralstat.

Publications

Patents

Pipeline